痛舒胶囊结合盐酸乙哌立松治疗颈源性头痛临床疗效及安全性研究

Clinical Efficacy and Safety of Tongshu Capsule(痛舒胶囊)Combined with Eperisone Hydrochloride in Treatment of Cervical Headache

目的探究痛舒胶囊结合盐酸乙哌立松治疗颈源性头痛临床疗效及安全性。方法研究共计纳入112例颈源性头痛患者,均由医院2017年7月—2020年1月收治,采取随机数字表法将其分为对照组和观察组,每组56例,对照组采取盐酸乙哌立松治疗,观察组在对照组治疗基础上联合痛舒胶囊治疗,比较两组临床疗效、治疗前后临床症状与体征(颈项痛、棘突旁压痛、条索状阳性反应物、上肢痛、头晕、失眠、工作能力)评分变化、治疗前后患者视觉模拟疼痛评分(VAS)及医学结局研究用疼痛量表(MOSPM)评分变化、治疗前后头痛发作次数及颈椎活动度评分(ROM)、治疗前后椎动脉血流参数变化、治疗前后患者生活质量(CHQOL)评分变化、治疗不良反应情况。结果观察组患者治疗总有效率(98.21%,55/56)高于对照组(85.71%,48/56),P<0.05;治疗前,两组患者临床症状与体征评分、VAS及MOSPM评分、头痛发作次数、ROM评分、脉动指数、阻力指数及平均血流速度等椎动脉血流参数、CHQOL评分比较,P>0.05,治疗后各组患者临床症状与体征评分、VAS及MOSPM评分、头痛发作次数、ROM评分、脉动指数、阻力指数及平均血流速度等椎动脉血流参数、CHQOL评分均改善,观察组患者治疗后临床症状与体征评分、VAS及MOSPM评分、头痛发作次数、ROM评分、脉动指数、阻力指数及平均血流速度等椎动脉血流参数、CHQOL评分各项指标均优于对照组,P<0.05;观察组未见不良反应,对照组出现1例胃肠道反应,P>0.05。结论痛舒胶囊结合盐酸乙哌立松治疗颈源性头痛临床疗效显著,患者症状及体征显著改善,疼痛次数降低,疼痛减轻,且颈椎活动度提升,生活质量提升,未见不良反应,安全性高,值得推广以及应用。

Objective To explore the clinical efficacy and safety of Tongshu Capsule(痛舒胶囊)combined with eperisone hydrochloride in the treatment of cervical headache.Methods A total of 112 patients with cervical headache who were admitted to our hospital from July 2017 to January 2020 were divided into two groups by random number table method.Patients in the control group(56 cases)were treated with eperisone hydrochloride,while those in the observation group(56 cases)were treated with Tongshu Capsule on the basis of treatment in the control group.We compared two groups’clinical efficacy,clinical symptoms and physical signs(neck pain,paraspinous tenderness,funicular positive reactant,upper limb pain,dizziness,insomnia,ability to work),visual analog pain score(VAS)and medical outcomes study with pain scale(MOSPM)score,the number of headache and cervical activity score(ROM),vertebral artery blood flow parameters,the quality of life(CHQOL)of the patients before and after treatment.The adverse reactions were recorded and compared.Results The total effective rate(98.21%,55/56)in the observation group was higher than that in the control group(85.71%,48/56)(P<0.05).Before treatment,two groups’clinical symptoms and signs scores,VAS,frequency MOSPM score,headache and ROM score,pulsating index and resistance index and average blood velocity of vertebral artery blood flow parameters and CHQOL had no significance(P>0.05).After treatment,the observation group’s clinical symptoms and signs scores,VAS,frequency MOSPM score,headache and ROM score,pulsating index and resistance index and average blood flow velocity,vertebral artery blood flow parameters,such as CHQOL score were improved.The scores of clinical symptoms and signs,VAS and MOSPM scores,headache attack times,ROM scores,pulse index,resistance index,mean blood flow velocity and other indicators of vertebral artery blood flow parameters and CHQOL scores in the observation group were better than those of the control group(P<0.05).No adverse reactions were observed in the observation group,and 1 case of gastrointestinal reaction was observed in the control group(P>0.05).Conclusion Tongshu Capsule combined with eperisone hydrochloride has a significant clinical effect in the treatment of cervical headache.It can significantly improve the symptoms and signs,reduce the pain frequency,alleviate the pain,and improve cervical mobility and the quality of life and there were no adverse reactions.The safety is high,and it is worthy of promotion and application.